Insider transactions

EDGAR

PLURI INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
1 transactions, 833,334 shares
Sum of shares × price per share: 1,250,001
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–20 of 20

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-23 Filed 2026-10-27Manieu Alexandre Weinstein Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)833,3341.50
1,250,001

Derived: shares × price per share. Exact value 1250001.00.

2,083,334Indirect (I) By Chutzpah Holdings LPNo
F2, F3
  • F2 On October 20, 2026, Chutzpah Holdings LP (CHLP) entered into a Securities Purchase Agreement with the Issuer (the October 2026 SPA), pursuant to which CHLP acquired, upon closing on October 23, 2026, 833,334 Common Shares and Common Warrants to purchase up to 833,334 Common Shares at an exercise price of $1.65 per share, for a purchase price of $1.50 per share and accompanying warrant, or $1,250,000 in the aggregate. The aggregate purchase price was satisfied in full through the application of the $1,250,000 advance payment made by CHLP to the Issuer on June 16, 2026 pursuant to the Advance Subscription Agreement dated June 14, 2026. No separate consideration was allocated to the warrants.
  • F3 The securities are held directly by CHLP, a limited partnership beneficially owned by Mr. Weinstein. Following the reported transaction, CHLP holds 2,083,334 Common Shares (consisting of 625,000 Common Shares acquired under the Securities Purchase Agreement dated December 8, 2025, 625,000 Common Shares acquired under the Securities Purchase Agreement dated March 24, 2026, and the 833,334 Common Shares reported herein). CHLP also holds warrants to purchase 625,000 Common Shares at an exercise price of $4.25 per share issued under the March 24, 2026 Securities Purchase Agreement, which are subject to a 35% beneficial ownership limitation. Mr. Weinstein disclaims beneficial ownership of the securities held by CHLP except to the extent of his pecuniary interest therein.
Open filing 0001213900-26-112641 Read from the filing’s XML Dispute this row
2026-10-23 Filed 2026-10-27Manieu Alexandre Weinstein Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Warrants — underlying Common Shares (833,334) — exercise price 1.65
Acquired (A)833,334——833,334Indirect (I) By Chutzpah Holdings LPNo
F2, F4, F3
  • F2 On October 20, 2026, Chutzpah Holdings LP (CHLP) entered into a Securities Purchase Agreement with the Issuer (the October 2026 SPA), pursuant to which CHLP acquired, upon closing on October 23, 2026, 833,334 Common Shares and Common Warrants to purchase up to 833,334 Common Shares at an exercise price of $1.65 per share, for a purchase price of $1.50 per share and accompanying warrant, or $1,250,000 in the aggregate. The aggregate purchase price was satisfied in full through the application of the $1,250,000 advance payment made by CHLP to the Issuer on June 16, 2026 pursuant to the Advance Subscription Agreement dated June 14, 2026. No separate consideration was allocated to the warrants.
  • F4 The Common Warrants become exercisable on the six-month anniversary of their issue date and expire on the fifth anniversary of such initial exercise date.
  • F3 The securities are held directly by CHLP, a limited partnership beneficially owned by Mr. Weinstein. Following the reported transaction, CHLP holds 2,083,334 Common Shares (consisting of 625,000 Common Shares acquired under the Securities Purchase Agreement dated December 8, 2025, 625,000 Common Shares acquired under the Securities Purchase Agreement dated March 24, 2026, and the 833,334 Common Shares reported herein). CHLP also holds warrants to purchase 625,000 Common Shares at an exercise price of $4.25 per share issued under the March 24, 2026 Securities Purchase Agreement, which are subject to a 35% beneficial ownership limitation. Mr. Weinstein disclaims beneficial ownership of the securities held by CHLP except to the extent of his pecuniary interest therein.
Open filing 0001213900-26-112641 Read from the filing’s XML Dispute this row
2026-08-25 Filed 2026-10-27Manieu Alexandre Weinstein Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6410—7,566Direct (D) No
F1
  • F1 Represents Common Shares received upon the vesting and settlement on August 25, 2026 of 641 restricted stock units (RSUs). Mr. Weinstein has been granted an aggregate of 10,769 RSUs: (i) 10,250 RSUs granted February 25, 2025 under the Company's 2016 Equity Compensation Plan, vesting in twelve quarterly installments (four grants of 1,281 shares from May 25, 2025 through February 25, 2026, and eight grants of 641 shares, the last being 639 shares, from May 25, 2026 through February 25, 2028); and (ii) 519 RSUs granted December 1, 2025 under the Company's 2019 Equity Compensation Plan, all of which vested in three monthly installments of 173 shares ending February 28, 2026. As of the date hereof, 6,925 RSUs have vested and settled into Common Shares held directly by Mr. Weinstein, 641 RSUs will vest on November 25, 2026, and the remaining 3,203 RSUs are unvested. Unvested RSUs confer no voting or dividend rights until settlement.
Open filing 0001213900-26-112641 Read from the filing’s XML Dispute this row
2026-08-20 Filed 2026-08-24SHORRER DORON Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)31,5690—38,228Direct (D) No
F1
  • F1 Consists of common shares underlying restricted stock units (RSUs) that were granted by the Board of Directors on August 20, 2026. The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.
Open filing 0001213900-26-093070 Read from the filing’s XML Dispute this row
2026-08-20 Filed 2026-08-24Manieu Alexandre Weinstein Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)180,0000—190,769Direct (D) No
F1, F2
  • F1 Consists of common shares underlying restricted stock units (RSUs) that were granted by the Board of Directors on August 20, 2026. The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.
  • F2 Includes 10,769 RSUs under two separate equity plan agreements, as previously reported.
Open filing 0001213900-26-093064 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Manieu Alexandre Weinstein Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6410—6,925Direct (D) No
F1
  • F1 Represents 6,284 Common Shares received upon vesting of restricted stock units (RSUs) and 641 RSUs that are scheduled to vest within 60 days of the date hereof. Mr. Weinstein has been granted an aggregate of 10,769 RSUs under two separate equity compensation plan agreements with the Company: (i) 10,250 RSUs granted on February 25, 2025, pursuant to the Company's 2016 Equity Compensation Plan, which vest in twelve installments through February 25, 2028; and (ii) 519 RSUs granted on December 1, 2025, pursuant to the Company's 2019 Equity Compensation Plan, which are fully vested. As of the date hereof, 6,284 RSUs have vested, and an additional 641 RSUs are scheduled to vest within 60 days of the date hereof. The remaining 3,844 RSUs are unvested and subject to future vesting conditions beyond 60 days.
Open filing 0001213900-26-074214 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Manieu Alexandre Weinstein Director · 10% owner
E

Expiration of short derivative position

Derivative security: Warrants — underlying Common Shares (625,000) — exercise price 4.25
Disposed (D)625,0000—0Indirect (I) Warrants indirectly held through Chutzpah Holdings LPNo
F2
  • F2 Under a Securities Purchase Agreement dated December 8, 2025 (the December 2025 SPA), Chutzpah Holdings LP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026) Under the terms of the December 2025 SPA, the Common Warrants to purchase 625,000 Common Shares expired on June 30, 2026, as being reported in this filing.
Open filing 0001213900-26-074214 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-05-04Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)312,5002.00
625,000

Derived: shares × price per share. Exact value 625000.00.

1,250,000Indirect (I) Shares indirectly held through Chutzpah Holdings LPNo
F1, F2, F3, F5, F6, F7
  • F1 On March 24, 2026, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the March 2026 SPA) with Chutzpah Holdings LP (CHLP), a limited partnership beneficially owned by Mr. Alexandre Weinstein (Mr. Weinstein), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share (Common Shares), and (ii) common warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:
  • F2 (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the December 2025 SPA), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).
  • F3 (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a Beneficial Ownership Limitation). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.
  • F5 The March 2026 SPA defines the Per Share Purchase Price as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.
  • F6 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. (Plantae) is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.
  • F7 (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the Exchange Act), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-051531 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-05-04Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants — underlying Common Shares (312,500) — exercise price 4.25
Acquired (A)312,5002.00
625,000

Derived: shares × price per share. Exact value 625000.00.

1,250,000Indirect (I) Warrants indirectly held through Chutzpah Holdings LPNo
F1, F2, F3, F10, F5, F6, F7
  • F1 On March 24, 2026, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the March 2026 SPA) with Chutzpah Holdings LP (CHLP), a limited partnership beneficially owned by Mr. Alexandre Weinstein (Mr. Weinstein), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share (Common Shares), and (ii) common warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:
  • F2 (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the December 2025 SPA), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).
  • F3 (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a Beneficial Ownership Limitation). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.
  • F10 The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.
  • F5 The March 2026 SPA defines the Per Share Purchase Price as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.
  • F6 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. (Plantae) is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.
  • F7 (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the Exchange Act), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-051531 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-05-04Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)312,5002.00
625,000

Derived: shares × price per share. Exact value 625000.00.

937,500Indirect (I) Shares indirectly held through Chutzpah Holdings LPNo
F1, F2, F3, F4, F5, F6, F7
  • F1 On March 24, 2026, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the March 2026 SPA) with Chutzpah Holdings LP (CHLP), a limited partnership beneficially owned by Mr. Alexandre Weinstein (Mr. Weinstein), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share (Common Shares), and (ii) common warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:
  • F2 (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the December 2025 SPA), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).
  • F3 (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a Beneficial Ownership Limitation). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.
  • F4 The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.
  • F5 The March 2026 SPA defines the Per Share Purchase Price as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.
  • F6 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. (Plantae) is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.
  • F7 (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the Exchange Act), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-051531 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-05-04Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants — underlying Common Shares (312,500) — exercise price 4.25
Acquired (A)312,5002.00
625,000

Derived: shares × price per share. Exact value 625000.00.

937,500Indirect (I) Warrants indirectly held through Chutzpah Holdings LPNo
F1, F2, F3, F4, F10, F5, F6, F7
  • F1 On March 24, 2026, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the March 2026 SPA) with Chutzpah Holdings LP (CHLP), a limited partnership beneficially owned by Mr. Alexandre Weinstein (Mr. Weinstein), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share (Common Shares), and (ii) common warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:
  • F2 (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the December 2025 SPA), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).
  • F3 (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a Beneficial Ownership Limitation). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.
  • F4 The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.
  • F10 The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.
  • F5 The March 2026 SPA defines the Per Share Purchase Price as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.
  • F6 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. (Plantae) is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.
  • F7 (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the Exchange Act), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-051531 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2026-01-05Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)625,0002.00
1,250,000

Derived: shares × price per share. Exact value 1250000.00.

625,000Indirect (I) Shares indirectly held through Chutzpah Holdings LPNo
F1, F2, F3
  • F1 On December 8, 2025, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the Securities Purchase Agreement) with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company (Mr. Weinstein), relating to a private placement offering (the Offering) of: (i) 625,000 common shares, par value $0.00001 per share (the Common Shares) of the Company, and (ii) warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.
  • F2 (Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.
  • F3 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-001394 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2026-01-05Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants — underlying Common Shares (625,000) — exercise price 4.25
Acquired (A)625,0002.00
1,250,000

Derived: shares × price per share. Exact value 1250000.00.

625,000Indirect (I) Warrants indirectly held through Chutzpah Holdings LPNo
F1, F2, F3
  • F1 On December 8, 2025, Pluri Inc. (the Company) entered into a Securities Purchase Agreement (the Securities Purchase Agreement) with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company (Mr. Weinstein), relating to a private placement offering (the Offering) of: (i) 625,000 common shares, par value $0.00001 per share (the Common Shares) of the Company, and (ii) warrants (the Common Warrants) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.
  • F2 (Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.
  • F3 This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP (CHLP), Chutzpah Holdings Limited (CHL), Plantae Bioscience Ltd. (Plantae) and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Open filing 0001213900-26-001394 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Zalts Liat Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,6600—92,767Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119232 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08YANAY YAKY Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,5880—497,758Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119234 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Levi Rami Avraham Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6530—18,967Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119233 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Aberman Zami Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3460—144,212Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119229 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Manieu Alexandre Weinstein Director · 10% ownerChutzpah Holdings Ltd 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)5190—10,769Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119238 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Shemesh-Rasmussen Maital Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6990—19,144Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119230 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-08Ajchenbaum Eitan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6680—12,353Direct (D) No
F1
  • F1 The restricted stock units (RSUs) were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.
Open filing 0001213900-25-119235 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Aberman Zami DirectorCommon Stock 11,472I By Rose Hitech Ltd.As of 2025-12-08 Open filing 4
Aberman Zami DirectorCommon Stock 144,212D As of 2025-12-04 Open filing 4
Ajchenbaum Eitan DirectorCommon Stock 12,353D As of 2025-12-04 Open filing 4
Birger Pinhas Doron DirectorCommon Stock 19,178D As of 2025-02-25 Open filing 4
Chutzpah Holdings Ltd 10% ownerWarrants Derivative security · underlying Common Shares84,599I Warrants indirectly held through Chutzpah Holdings LPAs of 2026-05-04 Open filing 4
Chutzpah Holdings Ltd Director · 10% ownerCommon Warrants Derivative security · underlying Common Shares84,599I Indirectly held through Chutzpah Holdings LimitedAs of 2025-01-23 Open filing 4
Chutzpah Holdings Ltd Director · 10% ownerPre-Funded Warrants to purchase Common Shares Derivative security · underlying Common Shares84,599I Indirectly held through Chutzpah Holdings LimitedAs of 2025-10-29 Open filing 4
Chutzpah Holdings Ltd 10% ownerWarrants Derivative security · underlying Common Shares1,250,000I Warrants indirectly held through Chutzpah Holdings LPAs of 2026-04-21 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 6,284D As of 2026-05-04 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 452,702I Plantae Biosciences Ltd.As of 2026-05-04 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LPAs of 2026-05-04 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LimitedAs of 2025-12-08 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 1,383,948I Shares indirectly held through Chutzpah Holdings Limited see NotesAs of 2025-02-18 Open filing 3
Chutzpah Holdings Ltd 10% ownerCommon Stock 452,702I Shares indirectly held through Plantae Bioscience Ltd.As of 2026-01-05 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 10,769D As of 2025-12-04 Open filing 4
Chutzpah Holdings Ltd 10% ownerCommon Stock 1,250,000I Shares indirectly held through Chutzpah Holdings LPAs of 2026-04-21 Open filing 4
Chutzpah Holdings Ltd Director · 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LimitedAs of 2025-10-29 Open filing 4
Chutzpah Holdings Ltd Director · 10% ownerCommon Stock 452,702I Shares indirectly held through Plantae Bioscience Ltd.As of 2025-04-28 Open filing 4
Levi Rami Avraham DirectorCommon Stock 18,967D As of 2025-12-04 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerWarrants Derivative security · underlying Common Shares84,599I Warrants indirectly held through Chutzpah Holdings LPAs of 2026-05-04 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Warrants Derivative security · underlying Common Shares84,599I Indirectly held through Chutzpah Holdings LimitedAs of 2025-01-23 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerPre-Funded Warrants to purchase Common Shares Derivative security · underlying Common Shares84,599I Indirectly held through Chutzpah Holdings LimitedAs of 2025-10-29 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerWarrants Derivative security · underlying Common Shares833,334I By Chutzpah Holdings LPAs of 2026-10-23 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerWarrants Derivative security · underlying Common Shares0I Warrants indirectly held through Chutzpah Holdings LPAs of 2026-06-30 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Shares 452,702I Plantae Biosciences Ltd.As of 2026-08-24 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Shares 1,250,000I Shares indirectly held through Chutzpah Holdings LPAs of 2026-08-24 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Shares 1,933,415I Shares indirectly held through Chutzpah Holdings Ltd.As of 2026-08-24 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 6,284D As of 2026-05-04 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 452,702I Plantae Biosciences Ltd.As of 2026-05-04 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LPAs of 2026-05-04 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LimitedAs of 2025-12-08 Open filing 4
Manieu Alexandre Weinstein 10% ownerCommon Stock 1,383,948I Shares indirectly held through Chutzpah Holdings Limited see NotesAs of 2025-02-18 Open filing 3
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 452,702I Shares indirectly held through Plantae Bioscience Ltd.As of 2026-01-05 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Shares 190,769D As of 2026-08-20 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 7,566D As of 2026-08-25 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 2,083,334I By Chutzpah Holdings LPAs of 2026-10-23 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 1,250,000I Shares indirectly held through Chutzpah Holdings LPAs of 2026-04-21 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 1,933,415I Shares indirectly held through Chutzpah Holdings LimitedAs of 2025-10-29 Open filing 4
Manieu Alexandre Weinstein Director · 10% ownerCommon Stock 452,702I Shares indirectly held through Plantae Bioscience Ltd.As of 2025-04-28 Open filing 4
SHORRER DORON DirectorCommon Stock 6,659D As of 2026-07-07 Open filing 3
SHORRER DORON DirectorCommon Stock 6,969I By Shorrer International Ltd.As of 2026-08-24 Open filing 4
SHORRER DORON DirectorCommon Stock 38,228D As of 2026-08-20 Open filing 4
Shemesh-Rasmussen Maital DirectorCommon Stock 19,144D As of 2025-12-04 Open filing 4
YANAY YAKY Director · Officer: Chief Executive OfficerStock Option Derivative security · underlying Common Stock39,050D As of 2025-10-15 Open filing 4
YANAY YAKY Director · Officer: Chief Executive OfficerCommon Stock 836I By Yaacov Yanay Management Ltd.As of 2025-12-08 Open filing 4
YANAY YAKY Director · Officer: Chief Executive OfficerCommon Stock 497,758D As of 2025-12-04 Open filing 4
Zalts Liat Officer: Chief Financial OfficerCommon Stock 92,767D As of 2025-12-04 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–18 of 18

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
ARMISTICE CAPITAL, LLC 1,200,077 SH1,200,077 dollarsNot in the prior quarter’s filings read Open filing 0001315863-26-000784 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager46,164 SH44,784 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager16,056 SH16,056 dollarsLower by 2,268 Prior quarter: 18,324Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager2,982 SH2,982 dollarsUnchanged Prior quarter: 2,982Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
EverSource Wealth Advisors, LLC 2,000 SH2,000 dollarsUnchanged Prior quarter: 2,000Open filing 0001710537-26-000009 Filed 2026-11-04 Dispute this row
UBS Group AG Partly reported under another manager504 SH504 dollarsLower by 1,414 Prior quarter: 1,918Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
BARCLAYS PLC Partly reported under another manager366 SH366 dollarsNot in the prior quarter’s filings read Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
SIMA Wealth Partners, LLC 350 SH350 dollarsUnchanged Prior quarter: 350Open filing 0002135539-26-000014 Filed 2026-10-19 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager185 SH185 dollarsUnchanged Prior quarter: 185Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager125 SH120 dollarsUnchanged Prior quarter: 125Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager125 SH0 dollarsUnchanged Prior quarter: 125Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
SBI Securities Co., Ltd. 97 SH97 dollarsUnchanged Prior quarter: 97Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
TD Waterhouse Canada Inc. Partly reported under another manager93 SH96 dollarsLower by 2 Prior quarter: 95Open filing 0002052595-26-000100 Filed 2026-10-16 Dispute this row
Activest Wealth Management Partly reported under another manager86 SH83 dollarsUnchanged Prior quarter: 86Open filing 0001883134-26-000005 Filed 2026-10-15 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager50 SH50 dollarsUnchanged Prior quarter: 50Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Winch Advisory Services, LLC 26 SH26 dollarsUnchanged Prior quarter: 26Open filing 0001580642-26-007561 Filed 2026-11-06 Dispute this row
TFC Financial Management, Inc. 19 SH19 dollarsUnchanged Prior quarter: 19Open filing 0001398344-26-018740 Filed 2026-10-26 Dispute this row
IFG Advisory, LLC 13 SH13 dollarsUnchanged Prior quarter: 13Open filing 0001728319-26-000008 Filed 2026-11-09 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • CITIGROUP INC 191 SH
  • MERCER GLOBAL ADVISORS INC /ADV 5 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

13F filers report holding between 8.36% and 8.83% of shares outstanding.

Quarter ending 2026-09-30, against 14,375,922 shares on the cover dated 2026-11-11.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 181,202,4851,269,3188,935
2026-06-30 172,40826,5919,178
2026-03-31 142,39527,0259,173
2025-12-31 152,39526,2879,222
2025-09-30 1914,43852,4548,469
2025-06-30 2214,56277,2228,516
2025-03-31 2014,31257,6248,518
2024-12-31 2214,14856,9298,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Chutzpah Holdings Limited COMMON STOCK, PAR VALUE $0.00001 PER SHARE17.192,018,014.0010/23/2026 Filed 2026-10-27SCHEDULE 13D/AAmendment 6Open filing 0001213900-26-112643 Dispute this row
Chutzpah Holdings LP COMMON STOCK, PAR VALUE $0.00001 PER SHARE17.872,083,334.0010/23/2026 Filed 2026-10-27SCHEDULE 13D/AAmendment 6Open filing 0001213900-26-112643 Dispute this row
Plantae Bioscience Ltd. COMMON STOCK, PAR VALUE $0.00001 PER SHARE3.88452,702.0010/23/2026 Filed 2026-10-27SCHEDULE 13D/AAmendment 6Open filing 0001213900-26-112643 Dispute this row
Alexandre Weinstein COMMON STOCK, PAR VALUE $0.00001 PER SHARE38.854,561,616.0010/23/2026 Filed 2026-10-27SCHEDULE 13D/AAmendment 6Open filing 0001213900-26-112643 Dispute this row
Armistice Capital, LLC Common Shares, par value $0.00001 per share9.991,266,508.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001172661-26-005250 Dispute this row
Steven Boyd Common Shares, par value $0.00001 per share9.991,266,508.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001172661-26-005250 Dispute this row
Chutzpah Holdings Ltd COMMON STOCK, PAR VALUE $0.00001 PER SHARE18.52,018,014.0006/30/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 5Open filing 0001213900-26-074213 Dispute this row
Chutzpah Holdings LP COMMON STOCK, PAR VALUE $0.00001 PER SHARE16.371,875,000.0006/30/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 5Open filing 0001213900-26-074213 Dispute this row
Plantae Bioscience Ltd. COMMON STOCK, PAR VALUE $0.00001 PER SHARE4.18452,702.0006/30/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 5Open filing 0001213900-26-074213 Dispute this row
Alexandre Weinstein COMMON STOCK, PAR VALUE $0.00001 PER SHARE35.004,352,641.0006/30/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 5Open filing 0001213900-26-074213 Dispute this row
Chutzpah Holdings Limited COMMON STOCK, PAR VALUE $0.00001 PER SHARE18.642,018,014.0004/21/2026 Filed 2026-05-01SCHEDULE 13D/AAmendment 4Open filing 0001213900-26-051095 Dispute this row
Chutzpah Holdings LP COMMON STOCK, PAR VALUE $0.00001 PER SHARE12.162,500,000.0004/21/2026 Filed 2026-05-01SCHEDULE 13D/AAmendment 4Open filing 0001213900-26-051095 Dispute this row
Plantae Bioscience Ltd. COMMON STOCK, PAR VALUE $0.00001 PER SHARE4.22452,702.0004/21/2026 Filed 2026-05-01SCHEDULE 13D/AAmendment 4Open filing 0001213900-26-051095 Dispute this row
Alexandre Weinstein COMMON STOCK, PAR VALUE $0.00001 PER SHARE34.986,284.0004/21/2026 Filed 2026-05-01SCHEDULE 13D/AAmendment 4Open filing 0001213900-26-051095 Dispute this row
Chutzpah Holdings Limited COMMON STOCK, PAR VALUE $0.00001 PER SHARE18.932,018,014.0012/30/2025 Filed 2026-01-05SCHEDULE 13D/AAmendment 3Open filing 0001213900-26-001393 Dispute this row
Chutzpah Holdings LP COMMON STOCK, PAR VALUE $0.00001 PER SHARE11.721,250,000.0012/30/2025 Filed 2026-01-05SCHEDULE 13D/AAmendment 3Open filing 0001213900-26-001393 Dispute this row
Plantae Bioscience Ltd. COMMON STOCK, PAR VALUE $0.00001 PER SHARE4.25452,702.0012/30/2025 Filed 2026-01-05SCHEDULE 13D/AAmendment 3Open filing 0001213900-26-001393 Dispute this row
Alexandre Weinstein COMMON STOCK, PAR VALUE $0.00001 PER SHARE0.055,643.0012/30/2025 Filed 2026-01-05SCHEDULE 13D/AAmendment 3Open filing 0001213900-26-001393 Dispute this row
Chutzpah Holdings Ltd COMMON STOCK, PAR VALUE $0.00001 PER SHARE18.962,018,014.0012/09/2025 Filed 2025-12-15SCHEDULE 13D/AAmendment 2Open filing 0001213900-25-121483 Dispute this row
Chutzpah Holdings LP COMMON STOCK, PAR VALUE $0.00001 PER SHARE11.751,250,000.0012/09/2025 Filed 2025-12-15SCHEDULE 13D/AAmendment 2Open filing 0001213900-25-121483 Dispute this row
Alexandre Weinstein COMMON STOCK, PAR VALUE $0.00001 PER SHARE0.044,189.0012/09/2025 Filed 2025-12-15SCHEDULE 13D/AAmendment 2Open filing 0001213900-25-121483 Dispute this row
Shayna LP Common Shares, par value $0.00001 per share4.99406,981.0009/30/2025 Filed 2025-10-14SCHEDULE 13G/AAmendment 3Open filing 0001213900-25-098726 Dispute this row
Carmel Argaman Investments Ltd. Common Shares, par value $0.00001 per share4.99406,981.0009/30/2025 Filed 2025-10-14SCHEDULE 13G/AAmendment 3Open filing 0001213900-25-098726 Dispute this row
Avraham Levin Holdings Ltd. Common Shares, par value $0.00001 per share4.99406,981.0009/30/2025 Filed 2025-10-14SCHEDULE 13G/AAmendment 3Open filing 0001213900-25-098726 Dispute this row
Avraham Levin Common Shares, par value $0.00001 per share4.99406,981.0009/30/2025 Filed 2025-10-14SCHEDULE 13G/AAmendment 3Open filing 0001213900-25-098726 Dispute this row
Shayna LP(1) Common Shares, par value $0.00001 per share8.13,354,058— Filed 2024-02-13SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-013340 Dispute this row
Carmel Argaman Investments Ltd. Common Shares, par value $0.00001 per share8.13,354,058— Filed 2024-02-13SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-013340 Dispute this row
Avraham Levin Holdings Ltd. Common Shares, par value $0.00001 per share8.13,354,058— Filed 2024-02-13SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-013340 Dispute this row
Avraham Levin Common Shares, par value $0.00001 per share8.13,354,058— Filed 2024-02-13SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-013340 Dispute this row
Regals Capital Management LP Common Stock, par value $0.00001 per share4.872,041,939— Filed 2024-02-01SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-008977 Dispute this row
Regals Fund LP Common Stock, par value $0.00001 per share4.872,041,939— Filed 2024-02-01SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-008977 Dispute this row
David M. Slager Common Stock, par value $0.00001 per share6.702,812,099— Filed 2024-02-01SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-008977 Dispute this row
Shayna LP(1) Common Shares, par value $0.00001 per share8.73,599,621— Filed 2023-09-15SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-077010 Dispute this row
Carmel Argaman Investments Ltd. Common Shares, par value $0.00001 per share9.43,890,883— Filed 2023-09-15SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-077010 Dispute this row
Guy David Shantser Common Shares, par value $0.00001 per share9.43,890,883— Filed 2023-09-15SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-077010 Dispute this row
Shayna LP Common Stock, par value $0.00001 per share9.03,599,621— Filed 2023-02-16SC 13GRead from the cover page textOpen filing 0001213900-23-012277 Dispute this row
Regals Capital Management LP Common Stock, par value $0.00001 per share3.981,554,939— Filed 2023-02-06SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-008417 Dispute this row
Regals Fund LP Common Stock, par value $0.00001 per share3.981,554,939— Filed 2023-02-06SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-008417 Dispute this row
David M. Slager Common Stock, par value $0.00001 per share5.902,305,877— Filed 2023-02-06SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-23-008417 Dispute this row
Regals Capital Management LP Common Stock, par value $0.00001 per share3.341,071,938— Filed 2022-01-26SC 13GRead from the cover page textOpen filing 0001213900-22-003700 Dispute this row
Regals Fund LP Common Stock, par value $0.00001 per share3.341,071,938— Filed 2022-01-26SC 13GRead from the cover page textOpen filing 0001213900-22-003700 Dispute this row
David M. Slager Common Stock, par value $0.00001 per share5.251,685,038— Filed 2022-01-26SC 13GRead from the cover page textOpen filing 0001213900-22-003700 Dispute this row
Adi Wolf Common Stock, par value $0.00001 per share9.83,121,918— Filed 2021-06-01SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-030106 Dispute this row
Clover Wolf Capital – Limited Partnership Common Stock, par value $0.00001 per share9.83,121,918— Filed 2021-06-01SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-030106 Dispute this row
Clover Wolf Ltd. Common Stock, par value $0.00001 per share9.83,121,918— Filed 2021-06-01SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-030106 Dispute this row
Adi Wolf Common Stock, par value $0.00001 per share15.94,077,589— Filed 2021-02-05SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-006960 Dispute this row
Clover Wolf Capital – Limited Partnership Common Stock, par value $0.00001 per share15.94,077,589— Filed 2021-02-05SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-006960 Dispute this row
Clover Wolf Ltd. Common Stock, par value $0.00001 per share15.94,077,589— Filed 2021-02-05SC 13G/AAmendment 3Read from the cover page textOpen filing 0001213900-21-006960 Dispute this row
ARK Investment Management LLC Common stock15.453,959,344— Filed 2021-01-11SC 13GRead from the cover page textOpen filing 0001104659-21-002913 Dispute this row
Adi Wolf Common Stock, par value $0.00001 per share15.13,848,583— Filed 2020-10-05SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-20-030120 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to PLURI INC.